Xin Lang Cai Jing·2025-12-09 04:17Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, including joint prostheses and spinal implants [2] - As of September 30, 2025, the company achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a significant increase of 213.21% year-on-year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 2 - On December 8, the company's stock price increased by 0.12%, with a trading volume of 19.47 million yuan [1] - The financing buy-in amount on December 8 was 3.33 million yuan, with a net financing buy-in of 1.57 million yuan, indicating strong investor interest [1] - The company's financing balance reached 36.83 million yuan, accounting for 0.53% of its market capitalization, which is above the 70th percentile of the past year [1]